ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
HRASLS2 promotes the growth and glycolysis of pancreatic cancer by enhancing the stability of ASPH.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains one of the deadliest forms, with limited treatment options and a grim prognosis. However, the role of HRASLS2 in pancreatic adenocarcinoma (PAAD) is still not fully understood. This study aimed to investigate the role of HRAS-like suppressor family 2 (HRASLS2) and its potential mechanisms in PAAD. In this study, HRASLS2 expression and its prognostic significance were analyzed using online databases. Cell Counting Kit-8 and Ethynyl-20-deoxyuridine (EdU) assays were used to assess the growth activity of pancreatic cancer cells. Glucose consumption, lactic acid production, and extracellular acidification rate (ECAR) were measured to assess glycolytic activity. A xenograft model was employed to explore the role of HRASLS2 in vivo. Here, we found that the expression of HRASLS2 was higher in PAAD tissues, positively associated with copy number variations, and negatively correlated with promoter methylation. High levels of HRASLS2 were linked to poor prognosis and tumor immune microenvironment. Functionally, HRASLS2 promoted the growth of pancreatic cancer cells both in vivo and in vitro. HRASLS2 knockdown inhibited the growth and glycolysis of pancreatic cancer cells. Mechanistically, HRASLS2 interacted with aspartate β-hydroxylase (ASPH) protein and increased its stability. Overexpression of ASPH reversed the inhibitory effects on cell growth and glycolysis caused by knockdown of HRASLS2 in pancreatic cancer cells. This investigation revealed a novel mechanism of HRASLS2 in promoting the growth and glycolysis of PAAD by upregulating ASPH protein and indicated that HRASLS2 may be a potential therapeutic strategy for PAAD.
Indexed as
Identifiers
40833600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.